Warringal Private Hospital
Welcome,         Profile    Billing    Logout  
 18 Trials 
30 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Tebbutt, Niall C
HERIZON-GEA-01, NCT05152147 / 2021-000296-36: A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers

Recruiting
3
918
Europe, Canada, Japan, RoW
Zanidatamab, ZW25, JZP598, Tislelizumab, Trastuzumab, Herceptin®, Capecitabine, Oxaliplatin, Cisplatin, 5-Fluorouracil
Jazz Pharmaceuticals, BeiGene, Ltd.
Gastric Neoplasms, Gastroesophageal Adenocarcinoma, Esophageal Adenocarcinoma
05/25
05/26
INTEGRATEIIb, NCT04879368 / 2020-004617-12: RegoNivo vs Standard of Care Chemotherapy in AGOC

Active, not recruiting
3
450
Europe, Japan, US, RoW
Regorafenib, Stivarga, Nivolumab, Opdivo, Docetaxel, Taxotere, Paclitaxel, Abraxane, Irinotecan, Camptosar, Trifluridine/Tipracil, Lonsurf
Australasian Gastro-Intestinal Trials Group, Bayer, Bristol-Myers Squibb, University of Sydney, Academic and Community Cancer Research United, Taiwanese Cooperative Oncology Group, Frankfurter Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, National Cancer Center Hospital East, Syneos Health
Gastro-Oesophageal Cancer
06/25
06/26
AZUR-2, NCT05855200: Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer

Recruiting
3
711
Europe, Canada, Japan, US, RoW
Dostarlimab, CAPEOX, FOLFOX
GlaxoSmithKline
Colonic Neoplasms, Neoplasms, Colon
12/28
12/30
ASPIRE, NCT05254171: Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Pancreatic Cancer

Recruiting
2/3
600
Europe, US, RoW
SBP-101, ivospemin, Nab-paclitaxel, Abraxane, Gemcitabine, Gemzar, Placebo
Panbela Therapeutics, Inc.
Pancreatic Cancer Metastatic, Pancreatic Ductal Adenocarcinoma, Pancreatic Cancer Stage IV
08/26
01/27
NEO-IMPACT, NCT06094140: NEO-adjuvant Chemo-immunotherapy in Pancreatic Cancer

Active, not recruiting
2
20
RoW
Durvalumab, Imfinzi, Oxaliplatin, Eloxatin, Irinotecan, Camptosar, Campto, Calcium folinate (leucovorin), Folinic acid, Fluorouracil, Adrucil, Pegylated G-CSF, Neulasta
Australasian Gastro-Intestinal Trials Group, The University of New South Wales, Walter and Eliza Hall Institute of Medical Research
Pancreatic Cancer
06/24
06/26
NCT06441747: Phase II Study of the Combination of Durvalumab (MEDI4736) (PDL1 Inhibitor) and Olaparib (PARP Inhibitor) in Advanced Cholangiocarcinoma After Initial Chemotherapy and Durvalumab (BIL-PPP)

Recruiting
2
40
RoW
Durvalumab, Imfinzi, Olaparib, Lynparza
Australasian Gastro-Intestinal Trials Group, Wayne Elphinstone Research Fund, AstraZeneca
Cholangiocarcinoma
08/26
08/28
ASCEND, NCT05042128: The Study: Gemcitabine and Nab-Paclitaxel With LSTA1 (Certepetide) or Placebo in Patients With Untreated Metastatic Pancreatic Ductal Adenocarcinoma

Active, not recruiting
2
158
RoW
LSTA1, CEND-1, certepetide, Gemcitabine Injection, Gemzar, Nab paclitaxel, Abraxane
Australasian Gastro-Intestinal Trials Group, University of Sydney
Pancreatic Ductal Adenocarcinoma, Metastatic Pancreatic Cancer
06/25
10/25
YH32367-101, NCT05523947: Clinical Trial of YH32367 in Patients with HER2 Positive Locally Advanced or Metastatic Solid Tumor

Recruiting
1/2
137
RoW
YH32367
Yuhan Corporation
HER2-Positive Solid Tumor
10/26
12/26
NCT05427487: Study of Intratumoral IVX037 in Patients With Advanced or Metastatic Solid Tumours

Recruiting
1
70
RoW
IVX037, Sintilimab
ImmVirx Pty Ltd, Innovent Biologics (Suzhou) Co. Ltd.
Colorectal Cancer, Gastric Cancer, Ovarian Cancer
09/26
11/26
Thibault, Bernard
REFINE-ICD, NCT00673842: Efficacy of Implantable Defibrillator Therapy After a Myocardial Infarction

Active, not recruiting
3
700
Europe, Canada, US, RoW
Implantable Cardioverter Defibrillator + Usual Care, Implantable Cardioverter Defibrillator, ICD, Usual care, Standard medical therapy alone
University of Calgary, Canadian Institutes of Health Research (CIHR), Alberta Innovation and Science, Medtronic, GE Healthcare, Cardiac Arrhythmia Network of Canada, Accelerating Clinical Trials Consortium
Myocardial Infarction, Sudden Death
12/24
12/24
BRAIN-AF, NCT02387229: Blinded Randomized Trial of Anticoagulation to Prevent Ischemic Stroke and Neurocognitive Impairment in AF

Terminated
3
1238
Canada
Rivaroxaban, Xarelto, standard of care
Montreal Heart Institute, Canadian Stroke Prevention Intervention Network, The Montreal Health Innovations Coordinating Center (MHICC), Bayer Healthcare Pharmaceuticals, Inc./Bayer Schering Pharma, Montreal Heart Institute Foundation, Canadian Institutes of Health Research (CIHR), Hewitt Foundation
ATRIAL FIBRILLATION
05/24
05/24
RAFT-PermAF, NCT01994252: Resynchronization/Defibrillation for Ambulatory Heart Failure Trial in Patients With Permanent Atrial Fibrillation

Active, not recruiting
N/A
200
Canada
Optimal Medical therapy plus ICD, Optimal Medical therapy plus CRT/ICD
Ottawa Heart Institute Research Corporation, Canadian Institutes of Health Research (CIHR)
Heart Disease, Congestive Heart Failure, Atrial Fibrillation
09/24
09/24
SyncAV, NCT04100148: Post-Market Trial

Active, not recruiting
N/A
1686
Europe, Canada, Japan, US, RoW
SyncAV programmed ON, Fixed AV delay
Abbott Medical Devices
Congestive Heart Failure
06/25
12/25
Essebag, Vidal
OCEAN, NCT02168829 / 2016-002353-38: Optimal Anticoagulation for Higher Risk Patients Post-Catheter Ablation for Atrial Fibrillation Trial

Active, not recruiting
4
1284
Europe, Canada, RoW
Rivaroxaban, Xarelto, Acetylsalicylic acid, Aspirin, ASA
Ottawa Heart Institute Research Corporation, Canadian Institutes of Health Research (CIHR), Bayer, Biotronik Canada Inc
Atrial Fibrillation, Stroke
07/25
08/25
REFINE-ICD, NCT00673842: Efficacy of Implantable Defibrillator Therapy After a Myocardial Infarction

Active, not recruiting
3
700
Europe, Canada, US, RoW
Implantable Cardioverter Defibrillator + Usual Care, Implantable Cardioverter Defibrillator, ICD, Usual care, Standard medical therapy alone
University of Calgary, Canadian Institutes of Health Research (CIHR), Alberta Innovation and Science, Medtronic, GE Healthcare, Cardiac Arrhythmia Network of Canada, Accelerating Clinical Trials Consortium
Myocardial Infarction, Sudden Death
12/24
12/24
RAFT-AF Extend, NCT05118893: Randomized Ablation-based AF Rhythm-control Versus Rate-control in Patients With HF and High-burden AF Extend

Recruiting
N/A
311
Canada
Anthony Tang
Atrial Fibrillation, Heart Failure
09/24
09/24
COAST-AF RCT, NCT03347227: Characterization of Arrhythmia Substrate to Ablate Persistent Atrial Fibrillation

Recruiting
N/A
502
Canada
Catheter ablation, Atrial Fibrillation Ablation
Ottawa Heart Institute Research Corporation, Heart and Stroke Foundation of Canada
Atrial Fibrillation
12/24
12/24
RAFT-PermAF, NCT01994252: Resynchronization/Defibrillation for Ambulatory Heart Failure Trial in Patients With Permanent Atrial Fibrillation

Active, not recruiting
N/A
200
Canada
Optimal Medical therapy plus ICD, Optimal Medical therapy plus CRT/ICD
Ottawa Heart Institute Research Corporation, Canadian Institutes of Health Research (CIHR)
Heart Disease, Congestive Heart Failure, Atrial Fibrillation
09/24
09/24
SyncAV, NCT04100148: Post-Market Trial

Active, not recruiting
N/A
1686
Europe, Canada, Japan, US, RoW
SyncAV programmed ON, Fixed AV delay
Abbott Medical Devices
Congestive Heart Failure
06/25
12/25
RASTA AF, NCT03682991: Reversal of Atrial Substrate to Prevent Atrial

Recruiting
N/A
670
Canada
Aggressive Risk Factor Control, Standard of Care
Nova Scotia Health Authority, Canadian Institutes of Health Research (CIHR), Abbott, Phillips, Cardiac Arrhythmia Network of Canada
Atrial Fibrillation
06/25
06/27
STARAF3, NCT04428944: STrategies for Catheter Ablation of peRsistent Atrial Fibrlllation

Recruiting
N/A
615
Europe, Canada, Japan, US, RoW
Wide Circumferential Pulmonary Vein Antrum Isolation (PVAI), Pulmonary Vein Antrum Isolation Plus Driver Ablation (PVAI+drivers), Pulmonary Vein Antrum Isolation Plus Box Isolation of Posterior Wall (PVAI+box)
McGill University Health Centre/Research Institute of the McGill University Health Centre, Montreal Heart Institute
Atrial Fibrillation
08/26
01/27
AWARE-2, NCT04823299: Patient Specific Ablation Strategy for Atrial Fibrillation (): A Randomized Clinical Trial

Not yet recruiting
N/A
390
Canada
Cryoballoon ablation, Radiofrequency catheter ablation +EPS guided trigger and substrate ablation
Ottawa Heart Institute Research Corporation, McGill University, University of British Columbia
Atrial Fibrillation, Catheter Ablation, Radiofrequency Catheter Ablation
09/26
09/26
NCT06048731: Enlighten Study: The EV-ICD Post Approval Registry

Recruiting
N/A
1000
Europe, Canada, US, RoW
Defibrillation using EV-ICD
Medtronic
Ventricular Arrhythmia, Tachycardia
05/30
10/37
O'Donnell, David
NCT03803969: ConfirmRxTM: Posture and Activity

Completed
N/A
100
RoW
ConfirmRx (Insertable Cardiac Monitor)
Abbott Medical Devices
Syncope, Cryptogenic Stroke
05/20
07/20
Nelson, Sonia
NCT03803969: ConfirmRxTM: Posture and Activity

Completed
N/A
100
RoW
ConfirmRx (Insertable Cardiac Monitor)
Abbott Medical Devices
Syncope, Cryptogenic Stroke
05/20
07/20
Ord, Michelle
NCT03803969: ConfirmRxTM: Posture and Activity

Completed
N/A
100
RoW
ConfirmRx (Insertable Cardiac Monitor)
Abbott Medical Devices
Syncope, Cryptogenic Stroke
05/20
07/20
Benoit, Marc
SyncAV, NCT04100148: Post-Market Trial

Active, not recruiting
N/A
1686
Europe, Canada, Japan, US, RoW
SyncAV programmed ON, Fixed AV delay
Abbott Medical Devices
Congestive Heart Failure
06/25
12/25
Guo, Yuan
NEO-IMPACT, NCT06094140: NEO-adjuvant Chemo-immunotherapy in Pancreatic Cancer

Active, not recruiting
2
20
RoW
Durvalumab, Imfinzi, Oxaliplatin, Eloxatin, Irinotecan, Camptosar, Campto, Calcium folinate (leucovorin), Folinic acid, Fluorouracil, Adrucil, Pegylated G-CSF, Neulasta
Australasian Gastro-Intestinal Trials Group, The University of New South Wales, Walter and Eliza Hall Institute of Medical Research
Pancreatic Cancer
06/24
06/26
ASCEND, NCT05042128: The Study: Gemcitabine and Nab-Paclitaxel With LSTA1 (Certepetide) or Placebo in Patients With Untreated Metastatic Pancreatic Ductal Adenocarcinoma

Active, not recruiting
2
158
RoW
LSTA1, CEND-1, certepetide, Gemcitabine Injection, Gemzar, Nab paclitaxel, Abraxane
Australasian Gastro-Intestinal Trials Group, University of Sydney
Pancreatic Ductal Adenocarcinoma, Metastatic Pancreatic Cancer
06/25
10/25
Paradise, NCT05671315: A Prospective Study to Evaluate Peginterferon in Reducing the Incidence of HCC in CHB Patients

Recruiting
N/A
267
RoW
Peginterferon alfa-2b Injection, Nucleos (t) ide Analogue, Nucleos(t)ide analogue
Qing XIe
Chronic Hepatitis B, Intermediate to High Risk of HCC
08/23
04/26

Download Options